Altamira Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Altamira Therapeutics has a total shareholder equity of CHF6.5M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF7.7M and CHF1.2M respectively.
Key information
0%
Debt to equity ratio
CHF0
Debt
| Interest coverage ratio | n/a |
| Cash | CHF617.41k |
| Equity | CHF6.46m |
| Total liabilities | CHF1.24m |
| Total assets | CHF7.69m |
Recent financial health updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Financial Position Analysis
Short Term Liabilities: CYTO's short term assets (CHF1.2M) exceed its short term liabilities (CHF888.9K).
Long Term Liabilities: CYTO's short term assets (CHF1.2M) exceed its long term liabilities (CHF346.6K).
Debt to Equity History and Analysis
Debt Level: CYTO is debt free.
Reducing Debt: CYTO has no debt compared to 5 years ago when its debt to equity ratio was 39.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYTO has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CYTO is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.